Halozyme Therapeutics (HALO) Accounts Payables (2010 - 2026)

Halozyme Therapeutics (HALO) has 17 years of Accounts Payables data on file, last reported at $14.1 million in Q1 2026.

• On a quarterly basis, Accounts Payables fell 29.77% year-over-year to $14.1 million in Q1 2026; TTM through Mar 2026 was $14.1 million, a 29.77% decrease from a year earlier, with the FY2025 full-year figure at $20.9 million, up 103.91% from the prior year.
• Accounts Payables for Q1 2026 stood at $14.1 million, down from $20.9 million in the prior quarter.
• Over the last five years, Accounts Payables for HALO reached as high as $20.9 million in Q4 2025 and fell as low as $1.3 million in Q1 2022.
• Historically, Accounts Payables has averaged $14.1 million across 5 years, with a median of $14.1 million in 2026.
• Across the five-year window, Accounts Payables surged 1048.15% in 2022 and tumbled 35.82% in 2024, its largest moves.
• Year by year, Accounts Payables stood at $17.7 million in 2022, then sank by 33.22% to $11.8 million in 2023, then retreated by 13.26% to $10.2 million in 2024, then jumped by 103.91% to $20.9 million in 2025, then plunged by 32.54% to $14.1 million in 2026.
• Per Business Quant data, the three most recent Accounts Payables figures were $14.1 million in Q1 2026, $20.9 million in Q4 2025, and $15.4 million in Q3 2025.